Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

Journal of the National Cancer Institute

Volumn 100, Issue 19, 2008, Pages 1380-1388

  Ellis, Matthew J ^a   Tao, Yu ^a   Luo, Jingqin ^a   A'Hern, Roger ^b   Evans, Dean B ^c   Bhatnagar, Ajay S ^c   Chaudri Ross, Hilary A ^c   Von Kameke, Alexander ^c   Miller, William R ^d   Smith, Ian ^e   Eiermann, Wolfgang ^f   Dowsett, Mitch ^e  

^a USA   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f Red Cross Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LETROZOLE; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NITRILES; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 53249154813     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn309     Document Type: Article

References (19)

1. Bast RC Jr, Hortobagyi GN. Individualized care for patients with cancer - a work in progress. N Engl J Med. 2004;351(27):2865-2867.
2. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25(19):2650-2655.
3. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527-1532.
4. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19(18):3808-3816.
5. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108-5116.
6. Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol. 2005;23(11):2477-2492.
7. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003;63(19):6523-6531.
8. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-168.
9. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99(2):167-170.
10. Katz RL, Patel S, Sneige N, et al. Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res Treat. 1990;15(3):191-203.
11. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031-2037.
12. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387.
13. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212-7220.
14. Ma CX, Ellis MJ. Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin Oncol. 2006;33(6):650-656.
15. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971-977.
16. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
17. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96-108.
18. Ellis MJ, Tao Y, Luo J, et al. A poor prognosis ER and HER2-negative, nonbasal, breast cancer subtype identified through postneoadjuvant endocrine therapy tumor profiling. J Clin Oncol. 2008;26:Abstract 502.
19. Ellis MJ. Neoadjuvant endocrine therapy as a drug development strategy. Clin Cancer Res. 2004;10(1 pt 2):391S-395S